Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

Company Plans To Expand Its Biosimilars Portfolio

Executive Summary

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.

You may also be interested in...



Cadila Pharma Adds To Indian Biosimilars With Adalimumab

After launching bevacizumab, rituximab and teriparatide biosimilars in the last two months, Cadila Pharma has added to the portfolio with the launch of Cadalimab (adalimumab) in India.

Biosimilar Avastin Is Launched In India

Outlining plans to launch “multiple biosimilar products this year for the Indian market,” Cadila Pharmaceutical has just rolled out a biosimilar to Avastin (bevacizumab) in its domestic market.

Teva Completes ‘Digihaler Family’

Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel